Skip to main content
. 2018 Sep 13;46(11):4377–4385. doi: 10.1177/0300060518786906

Table 3.

Sensitivity analysis of pooled SMD for AGEs and OSAHS under the random-effects model.

Study omitted SMD (95% CI) P for heterogeneity I2
Lam et al. 1.08 (0.74–1.42) 0.10 53%
Tan et al. 1.08 (0.68–1.47) 0.11 51%
Ji et al. 0.83 (0.64–1.02) 0.38 2%
Xue and Lin 0.95 (0.61–1.28) 0.07 58%
Kotani et al. 0.97 (0.64–1.31) 0.05 62%

SMD, standardized mean difference; CI, confidence interval; AGEs, advanced glycation end products; OSAHS, obstructive sleep apnea–hypopnea syndrome